YTHDF2 and neoplasm: Noises from these nontumorigenic cells cannot be ruled out in the co‐IP assay performed in fresh HCC tissues; second, co‐IP conditions by antibodies are lacking stringency to exclude ubiquitylation signals from YTHDF2 binding proteins as contaminants; third, the effects of sorafenib in combination with NVP‐AUY922 on sorafenib‐resistant model from clinical patients with HCC (such as patient‐derived tumor xenograft) need to be further explored in future.